Article
Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.
Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.
All News
Article
Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.
Article
Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.
Article
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
Dr. John Cush
Tweet
ICYMI: Risks associated with mortality in VEXAS
https://t.co/mpAc5shaMq https://t.co/FdOQcfwusp
Dr. John Cush
Tweet
ICYMI: Zoom Fatigue is real. Study shows fatigue is from being on-cam that triggers self-presentation - the needs to monitor how you look to others; more common in women. Suggest: reduce monitor/image size & Turn off Self view (avoid self evaluation) https://t.co/vS8tJv9Kpd https://t.co/F7mHdYgOXy
Dr. John Cush
Tweet
New podcast up!
Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.
Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.
https://t.co/oe6hsAq2KG https://t.co/1sbTmd9cnV
Dr. John Cush
Tweet
Download Available! The Scary Side of Steroid.
Log in and download today.
https://t.co/sYVWGTVHgx https://t.co/NIbi49SJEo
Dr. John Cush
Tweet
AURORA 2 results were presented at #ACR21 - a continuation study of voclosporin in 116 active Lupus Nephritis pts randomized to either PBO or voclosporin. After 36 mos the VOC group had stable GFR and reduction in proteinuria https://t.co/O7G1dCIzbP
Dr. John Cush
Tweet
ASK CUSH ANYTHING!
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/tl3Nkxdv0B https://t.co/WwxgWGuVcC
Dr. John Cush
Tweet
Check out our blog by Dr. Kathryn Dao ( @KDAO2011) on "Redefining Aging."
https://t.co/GbE77GTa0y https://t.co/e2GYETqsUR
Dr. John Cush
Tweet
CBD and Opioids in PsA : Dr. Eric Ruderman ( @JointMD) reviews abstract #1456 and #1777 presented at the ACR21 annual meeting.
https://t.co/ZATSfzqj51 https://t.co/dhFwgS9b6J
Dr. John Cush
Tweet
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
https://t.co/RbOlrnW54O https://t.co/iDlqwv32zs
Dr. John Cush
Tweet
Zoom Fatigue is real. Study shows fatigue is from being on-cam that triggers self-presentation - the needs to monitor how you look to others; more common in women. Suggest: reduce monitor/image size & Turn off Self view (avoid self evaluation) https://t.co/KYi8bMKURy https://t.co/8fUqdpe6ia
Dr. John Cush
Tweet
BMS has announced they have filed a new drug application with the FDA and EMA for Deucravacitinib, a TYK2 inhibitor, to treat adults with moderate to severe plaque psoriasis. (w/ a PDUFA goal date of 9/10/2022) https://t.co/w5YmRYdXm4
Dr. John Cush
Tweet
Improving Our Everyday RA Practice
https://t.co/eGPRMBGFjh https://t.co/y49x8MX4dK
Dr. John Cush
Tweet
The Gift of Gab: "RHEUM"
Dr. Eric Dein interviews Professor Zeide and Dr. Jason Liebowitz about a lively ACR21 talk called, "The Gift of Gab," which guided attendees on how to improve their communications.
https://t.co/fWOETKqQeP https://t.co/5b5rXzEAaQ
Dr. John Cush
Tweet
Cognitive Function and Rheumatoid Arthritis: Dr. Akhil Sood Interviews Dr. Elena Myasoedova
https://t.co/k3SBwEg0WH https://t.co/1eEBUQdMAa
Dr. John Cush
Tweet
RheumNow Live will be held in person AND virtually on March 19 and 20 in Irving, TX.
Register Today!
https://t.co/ntNiWwjkFU https://t.co/NfFHgVxXa2
Dr. John Cush
Tweet
Risks associated with mortality in VEXAS
https://t.co/6FIzZjlB0c https://t.co/YVoKOymWCX
